Xalkori Granted New Indication to Treat Non-Cancerous Tumors
July 14, 2022
FDA Approves First Therapy for Repigmentation in Vitiligo
July 19, 2022
July 15, 2022 – ZonisadeTM (zonisamide oral suspension) has received FDA approval to provide adjunctive therapy for the treatment of partial onset seizures in patients who are at least 16 years old.
- Zonisade is a new formulation of the active pharmaceutical ingredient (API) zonisamide. An oral capsule formulation, approved for use in adults and sold by Concordia under the brand name Zonegran®, received FDA approval in 2000. The oral capsule version is also available as a generic.
- Recommended dosing for Zonisade is 100mg daily. This can be increased by 100mg daily every two weeks, based on clinical response and tolerability, to 400mg daily. Patients who tolerate treatment at 400mg daily and require further reduction of seizures may have their dosage increased up to a maximum of 600mg daily.
- Eton Pharmaceuticals, the manufacturer, has not yet announced launch or pricing plans for Zonisade.